7.2 New Jersey Prescription Monitoring Program (NJPMP) Compliance

7.2 New Jersey Prescription Monitoring Program (NJPMP) Compliance

[!NOTE] Core Statutory Framework: The New Jersey Prescription Monitoring Program (NJPMP) is established pursuant to N.J.S.A. 45:1-45 through 45:1-49 and governed by administrative rules promulgated by the New Jersey Division of Consumer Affairs (DCA) at N.J.A.C. 13:45A-35. Additional clinical mandates regarding opioid prescribing limits and monitoring stem from P.L. 2017, c. 28.

The New Jersey Prescription Monitoring Program (NJPMP) is an electronic database operated by the New Jersey Division of Consumer Affairs that tracks the dispensing of controlled dangerous substances and designated drugs of concern. The program serves as a critical clinical and regulatory tool to curb prescription drug misuse, identify drug diversion and doctor shopping, promote responsible opioid prescribing, and protect public health. Compliance with NJPMP reporting, querying, and confidentiality rules is among the most heavily tested areas on the New Jersey MPJE.

---

Mandatory Daily Reporting & Covered Substances

Under N.J.S.A. 45:1-45 and N.J.A.C. 13:45A-35.4, every pharmacy permit holder that dispenses prescription drugs to outpatients in New Jersey—including retail community pharmacies, out-of-state mail-order pharmacies permitted in New Jersey, and institutional pharmacies dispensing outpatient discharge prescriptions—must report dispensing data to the NJPMP clearinghouse.

1. Transmission Frequency: The Daily Rule

Dispensing records must be submitted electronically to the NJPMP on a daily basis. The Division of Consumer Affairs and the NJPMP administrator state the deadline as within 24 hours of dispensation — note that this is a 24-hour clock rather than a "next business day" clock, so a Friday or Saturday dispensing does not wait until Monday. Gabapentin became reportable on May 7, 2018, which is why older study material lists only CDS and Human Growth Hormone. If a pharmacy does not dispense any reportable substances on a given business day, it must submit a "Zero Report" to maintain continuous compliance audit trails.

2. Format Specification

Submissions must adhere to the standardized electronic format established by the American Society for Automation in Pharmacy (ASAP) for prescription monitoring programs (e.g., ASAP Version 4.2 or higher).

3. Reportable Substances in New Jersey

The scope of reportable drugs in New Jersey extends beyond federal controlled substance schedules. Pharmacists must recognize the exact statutory list:

+---------------------------------------------------------------------------------------------------+
|                         NJPMP MANDATORY REPORTABLE SUBSTANCES IN NEW JERSEY                       |
+---------------------------------------------------------------------------------------------------+
| 1. Schedule II Controlled Dangerous Substances (e.g., oxycodone, fentanyl, amphetamine)           |
| 2. Schedule III Controlled Dangerous Substances (e.g., buprenorphine, acetaminophen/codeine)      |
| 3. Schedule IV Controlled Dangerous Substances (e.g., alprazolam, clonazepam, zolpidem, tramadol) |
| 4. Schedule V Controlled Dangerous Substances (e.g., pregabalin, promethazine with codeine)       |
| 5. Human Growth Hormone (HGH / Somatropin) (specifically designated by NJ statute)                |
| 6. Gabapentin (Neurontin) (specifically designated by NJ statute as a drug of concern)           |
+---------------------------------------------------------------------------------------------------+

[!WARNING] High-Yield MPJE Trap: Gabapentin & Human Growth Hormone (HGH): Neither Gabapentin nor Human Growth Hormone is classified as a controlled substance under federal law or the federal Controlled Substances Act (CSA). However, under New Jersey law, Gabapentin and HGH are statutorily mandated reportable drugs to the NJPMP. MPJE questions frequently test whether non-controlled gabapentin must be reported to the state database. In New Jersey, the answer is an absolute YES.

4. Mandatory Data Fields

Under N.J.A.C. 13:45A-35.4, each daily transmission must capture detailed transactional elements:

• Patient full legal name, street address, and date of birth.
• Patient telephone number and gender code.
• National Drug Code (NDC) of the medication dispensed.
• Metric quantity dispensed and estimated days supply.
• Date prescription was issued by prescriber and date actually dispensed by pharmacy.
• Prescription serial number (Rx number) and refill number.
• Prescriber's full name, National Provider Identifier (NPI), and DEA registration number.
• Pharmacy's name, NPI number, and DEA registration number.
• Method of Payment: Cash, commercial private insurance, Medicaid, Medicare, or workers' compensation (crucial for detecting cash-payment diversion).

5. Statutory Exemptions from Reporting

Reporting is NOT required for:

1. Direct administration of a controlled substance to an inpatient in a hospital, hospice, or long-term care nursing facility (24-hour medical care).
2. Dispensing of a 48-hour or less emergency supply of a controlled substance in an emergency department or urgent care setting.

---

Mandatory Prescriber Consultation Rules

Under N.J.S.A. 45:1-46.1 and P.L. 2017, c. 28, licensed prescribers (physicians, dentists, podiatrists, advanced practice nurses, physician assistants) are subject to affirmative statutory mandates to query the NJPMP:

1. Initial Prescription Mandate: The prescriber MUST query the NJPMP the first time they write a prescription for a Schedule II controlled substance or any opioid drug to an adult or pediatric patient for acute or chronic pain.
2. Quarterly Ongoing Therapy Mandate: For patients undergoing ongoing, continuous therapy with a Schedule II CDS or opioid drug, the prescriber MUST query the NJPMP at least quarterly (every 3 months) prior to issuing subsequent prescriptions.
3. Prescriber Documentation: The prescriber must document the date of the NJPMP query and clinical findings in the patient's permanent medical record.
4. Exceptions: Prescribers are exempt from querying the NJPMP if the controlled substance is prescribed for a patient in active hospice care, palliative cancer treatment, or immediately prior to surgical or invasive procedures in an inpatient facility.

---

Mandatory Pharmacist Consultation: The "Reasonable Belief" Standard

New Jersey law balances clinical judgment with statutory mandates regarding when a dispensing pharmacist must consult the NJPMP.

1. The Statutory Standard: Reasonable Belief (N.J.S.A. 45:1-46)

A licensed pharmacist MUST query the NJPMP whenever the pharmacist possesses a "reasonable belief" that a patient or individual presenting a prescription is seeking a controlled dangerous substance for any reason other than the legitimate treatment of an existing medical condition. This includes suspicions of:

• Prescription drug diversion or illicit re-sale.
• Doctor shopping (obtaining overlapping CDS prescriptions from multiple independent prescribers).
• Prescription forgery, blank theft, or altered quantities.
• Medication misuse, abuse, or dangerous polypharmacy.

2. Administrative & Board Expectations: Initial Schedule II Dispensing

Under Board of Pharmacy practice standards and collaborative Division of Consumer Affairs guidance, pharmacists are expected to consult the NJPMP prior to dispensing an initial Schedule II controlled substance to a patient with whom the pharmacy does not have an established dispensing relationship, or whenever clinical "red flags" are present. Failing to check the NJPMP in the face of glaring red flags violates the pharmacist's corresponding responsibility under 21 CFR § 1306.04 and N.J.A.C. 13:45H-7.4.

---

Recognizing Clinical & Operational Red Flags

Pharmacists are held to a strict legal "corresponding responsibility" to ensure prescriptions are issued for a legitimate medical purpose in the usual course of professional practice. When reviewing controlled substance orders, pharmacists must recognize behavioral, geographic, and pharmacological red flags:

+---------------------------------------------------------------------------------------------------+
|                             CONTROLLED SUBSTANCE RED FLAG TAXONOMY                                |
+---------------------------------------------------------------------------------------------------+
| FINANCIAL RED FLAGS:                                                                              |
|   ├── Insistence on paying cash when patient has active commercial or Medicaid insurance on file. |
|   └── Reluctance to bill insurance or presenting different names/cash cards.                      |
+---------------------------------------------------------------------------------------------------+
| BEHAVIORAL & TEMPORAL RED FLAGS:                                                                  |
|   ├── Pattern of early refill requests (e.g., requesting refills 5-10 days early every month).   |
|   ├── Patient appears overly nervous, agitated, or evasive when questioned about diagnosis.      |
|   └── Different individuals presenting identical prescriptions written by the same prescriber.    |
+---------------------------------------------------------------------------------------------------+
| GEOGRAPHIC RED FLAGS:                                                                             |
|   ├── "Pharmacy Shopping": Patient bypasses dozens of retail pharmacies to fill in distant town.  |
|   └── "Prescriber Shopping": Prescriber, patient, and pharmacy are located miles apart (>30 mi). |
+---------------------------------------------------------------------------------------------------+
| PHARMACOLOGICAL & DOSING RED FLAGS:                                                               |
|   ├── High Morphine Milligram Equivalents: Regimens exceeding 50 or 90 MME/day.                   |
|   ├── Dangerous Cocktails: Concurrent Opioids + Benzodiazepines (e.g., Oxycodone + Xanax).        |
|   └── The "Holy Trinity": Opioid + Benzodiazepine + Muscle Relaxant (e.g., Carisoprodol / Soma).  |
+---------------------------------------------------------------------------------------------------+

When red flags are identified, the pharmacist cannot simply dispense or turn a blind eye. The pharmacist must:

1. Check the NJPMP across state lines (interstate PMP data-sharing through PMP InterConnect).
2. Contact the prescriber to verify diagnosis, treatment plan, and legitimate medical necessity.
3. Document all verification steps, clinical rationale, and prescriber discussions on the prescription or dispensing system audit trail.

---

Delegate Access & Credentialing Standards

To facilitate clinical workflow, New Jersey law allows licensed prescribers and pharmacists to authorize delegates to query the NJPMP on their behalf.

1. Authorized Delegate Roles

Under N.J.S.A. 45:1-46(c), authorized delegates in a pharmacy setting include:

• Registered Pharmacy Technicians registered with the New Jersey State Board of Pharmacy.
• In medical practices, licensed nurses, certified medical assistants, or designated clinical support staff.

2. Delegate Account Registration

• Every delegate must apply for and maintain their own individual, unique user account with the Division of Consumer Affairs / NJPMP.
• The supervising pharmacist must formally sponsor and approve the delegate's account in the NJPMP system.
• Delegates must complete mandatory training on patient privacy, system navigation, and statutory compliance.

[!CAUTION] Strict Prohibition on Credential Sharing: A pharmacist or prescriber can NEVER share their login credentials, username, or password with a pharmacy technician, intern, or any other staff member. Credential sharing is a direct violation of state security regulations. If a technician needs to access the NJPMP, they must log in using their own registered delegate credentials under the direct supervision of the pharmacist.

3. Ultimate Pharmacist Responsibility

The supervising pharmacist retains complete legal, professional, and disciplinary responsibility for all queries conducted by their delegates. If a delegate accesses records unlawfully, the supervising pharmacist may face Board sanctions for failure of adequate supervision.

---

Confidentiality, Data Security & Statutory Penalties

Data stored in the NJPMP constitutes highly sensitive, confidential protected health information (PHI).

1. Non-Public Record Status

Under N.J.S.A. 45:1-47, NJPMP records are NOT public records and are strictly exempt from disclosure under New Jersey's Open Public Records Act (OPRA), subpoenas in civil litigation, and general discovery requests.

2. Law Enforcement Access

Law enforcement officers cannot freely browse the NJPMP. To obtain patient dispensing data, law enforcement agencies must submit an official request certified under oath confirming that the request relates to a bona fide, active criminal investigation of a specific named individual, or present a valid court order issued by a judge.

3. Severe Statutory Penalties for Misuse

Any person who knowingly accesses, alters, copies, or discloses NJPMP data without authorization or for personal curiosity (e.g., looking up family members, celebrities, or colleagues) is subject to severe multi-tiered penalties:

• Civil Monetary Penalties: Fines exceeding $10,000 per occurrence assessed by the Division of Consumer Affairs (N.J.S.A. 45:1-49).
• Administrative Disciplinary Sanctions: Immediate suspension, revocation, or probation of the pharmacist's or technician's professional license/registration by the Board of Pharmacy.
• Criminal Prosecution: Unlawful disclosure is punishable as a crime of the fourth degree or third degree under New Jersey criminal statutes, carrying potential imprisonment.